Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05185505 · ClinicalTrials.gov registry record · Phase 4
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
A Phase 4 study of Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05185505 is a Phase 4 study of Hepatocellular Carcinoma and Hepatocellular Cancer that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 24 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05185505, a Phase 4 study of Hepatocellular Carcinoma and Hepatocellular Cancer, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (1)
Texas
- Houston Methodist Research Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05185505
The ClinicalTrials.gov registry entry for NCT05185505 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05185505 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05185505 about?
NCT05185505 is a clinical study titled "Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria". Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bev...
What is the current status of trial NCT05185505?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2023-01-30. Estimated completion is 2027-10-31.
What conditions does trial NCT05185505 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatocellular Cancer.
What interventions are being tested in trial NCT05185505?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT05185505?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05185505 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
RECRUITING · Phase 4
-
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 4
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.